Scott Grindrod

This inventor holds 9 USPTO granted patents and 7 published patent applications and 4 EPO patents. Top assignee: Shuttle Pharmaceuticals, Inc.. Active years: 2017-2025.

USPTO Granted Patents = 9 (Patent Applications = 7)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Rockville, MD (US) (2017 - 2023)
Falls Church, VA (US) (2022 - 2024)

Company Filing History:

9 out of 9

Shuttle Pharmaceuticals, Inc.

patents

Years Active: 2017-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12357650 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation (2025-07-15),

2. 12077515 - Selective histone deacetylase inhibitors for the treatment of human disease (2024-09-03),

3. 11654157 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation (2023-05-23),

4. 11584733 - Selective histone deacetylase inhibitors for the treatment of human disease (2023-02-21),

5. 11407723 - Selective histone deacetylase inhibitors for the treatment of human disease (2022-08-09),

6. 11034667 - Selective histone deacetylase inhibitors for the treatment of human disease (2021-06-15),

7. 10745352 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-18),

8. 10730834 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-04),

9. 9809539 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2017-11-07),

Title: Scott Grindrod: Innovator in Cancer Therapy

Introduction

Scott Grindrod is a prominent inventor based in Rockville, MD (US), known for his significant contributions to cancer therapies. With a total of 9 patents, he has made remarkable strides in the field of medical innovation.

Latest Patents

Among his latest patents, Grindrod has developed methods and compositions for cancer therapies that include the delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation. This innovative approach provides new methods and formulations for treating cancer and neoplastic diseases alongside radiation therapy. His work includes a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent. Additionally, he has created selective histone deacetylase inhibitors for the treatment of human diseases. These selective HDAC inhibitors and their pharmaceutical compositions are designed for treating cancer, immunological diseases, inflammatory diseases, and neurological diseases.

Career Highlights

Grindrod's career is marked by his dedication to advancing cancer treatment through innovative research and development. His work has not only contributed to the scientific community but has also provided hope for patients battling various forms of cancer.

Collaborations

He has collaborated with notable colleagues, including Anatoly Dritschilo and Mira Jung, to further enhance the impact of his research and innovations in the medical field.

Conclusion

Scott Grindrod's contributions to cancer therapy through his patents and collaborative efforts highlight his commitment to improving patient outcomes. His innovative approaches continue to pave the way for advancements in medical treatments.